CureGene’s CG-0255 Receives NMPA Approval for Ischemic Stroke Trial – First Thiol-Based P2Y12 Inhibitor
Shanghai CureGene Pharmaceutical Co., Ltd announced it has received clinical trial approval from China’s National...
CureGene Pharmaceutical
Shanghai CureGene Completes Series B+ Financing to Advance CG-0255 Study
China-based Shanghai CureGene Pharmaceutical Co., Ltd announced the completion of a Series B+ financing round,...
CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255
Shanghai-based CureGene Pharmaceutical has announced receiving clinical trial approval from China’s National Medical Products Administration...
Shanghai CureGene Pharmaceutical Secures USD 14 Million in Series B Financing to Advance Cardiovascular Treatments
Shanghai CureGene Pharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has announced the successful completion of...